サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1362961

融合生検（フュージョン生検）の市場規模、シェア、動向分析レポート：生検ルート別、最終用途別、地域別、セグメント予測、2023年～2030年

Fusion Biopsy Market Size, Share & Trends Analysis Report By Biopsy Route (Transrectal, Transperineal), By End-use (Hospitals, Diagnostic Centers, Ambulatory Care Centers), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 100 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
融合生検（フュージョン生検）の市場規模、シェア、動向分析レポート：生検ルート別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月11日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

融合生検（フュージョン生検）市場の成長と動向：

Grand View Research, Inc.の新しいレポートによると、世界の融合生検市場規模は2030年までに11億1,560万米ドルに達し、予測期間中にCAGR 8.6％で進展すると予測されています。

前立腺がんの有病率の増加、標的生検に対する需要の高まり、前立腺がん治療における多波長MRIの利用率の上昇は、予測期間中に市場を牽引すると予想される要因です。さらに、日常的な治療介入の価値に対する意識の高まりや新たな償還政策などの要因が、融合生検市場の需要を促進すると予測されます。

TRUS生検、PSA検査、直腸指診などの他の従来技術に比べ、標的融合生検は前立腺病変の描出において感度と特異性が高いため、市場成長に寄与すると予想されます。進行性腫瘍の診断における融合生検システムの信頼性と再現性は、前立腺生検における標準的なツールになると予想されます。PI-RADSやグリソンスコアのような標準的な画像分類システムの導入と相まって、前立腺MRIの読影に関する専門知識を得る放射線科医が増加していることが、標的MR/超音波融合生検システムの利用率を高めています。

前立腺がんに関連する研究への資金提供、意識の普及、集団検診プログラムの実施といった点で、政府のイニシアチブの増加が市場の成長に重要な役割を果たすと予想されます。市場参入企業が採用する成長戦略には、この競争の激しい領域で成長を促進・維持するためのパートナーシップ、製品発表、展示会や会議への参加、買収などがあります。

融合生検市場レポートハイライト

  • 前立腺融合生検のゴールドスタンダードかつ一般的な方法であるため、経直腸部門が2022年に最大の市場シェアを占めました。
  • 経直腸セグメントは、安全性、診断効率、腹側前立腺領域へのアクセス能力により、予測期間中に最も速い速度で成長すると予想されます。
  • 病院セグメントは、教育病院におけるMR/米国標的融合生検システムの調達率増加などの要因により、2022年に最大の収益シェアを占めました。
  • 診断センターセグメントは、予測期間中にかなりの速度で拡大すると予想されています。待ち時間の短縮、コスト効率、発展途上の償還パラダイムがこのセグメントの成長を促進する要因です。
  • 北米は2022年に最大の市場シェアを占め、予測期間中もその優位性を維持すると予測されています。
  • アジア太平洋は、予測期間中にCAGR 9.9%になると予測されています。これは、特に日本、オーストラリア、中国などの国々で、泌尿器科医の間でMRI/米国標的融合生検システムの感度と特異性に関する認識が高まっていることなどの要因によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 融合生検市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 業界のバリューチェーン分析
    • 償還の枠組み
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 融合生検市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • 主要取引と戦略的提携の分析
    • 市場参入戦略
    • COVID-19感染症の影響分析

第4章 融合生検市場：生検ルートの推定・動向分析

  • 定義と範囲
  • 生検ルートの市場シェア、2022年と2030年
  • セグメントダッシュボード
  • 生検ルート別の世界の融合生検市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第5章 融合生検市場：最終用途の推定・動向分析

  • 定義と範囲
  • 最終用途の市場シェア、2022年と2030年
  • セグメントダッシュボード
  • 最終用途別の融合生検市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第6章 融合生検市場：地域の推定・動向分析

  • 地域の市場シェア分析、2022年と2030年
  • 地域の市場ダッシュボード
  • 地域の市場スナップショット
  • 地域の市場シェアと主要企業、2022年
  • SWOT分析、要因別（政治・法律、経済・技術）
  • 2022年から2030年の市場規模、予測および動向分析
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • タイ
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
    • イノベーター
    • 市場のリーダー
    • 新興選手
  • ベンダー情勢
  • 公開会社
    • 企業の市況分析（収益、地理的プレゼンス、製品ポートフォリオ、主要なサービス可能な産業、主要な提携）
    • 地域別の企業市場シェア/ランキング
    • 競合ダッシュボード分析
  • 非公開会社
    • 主要な新興企業/テクノロジーディスラプター/イノベーターのリスト
    • 資金調達の見通し
    • 地域ネットワークマップ
    • 企業の市況分析（地理的プレゼンス、製品ポートフォリオ、主要な提携、業界経験）
    • サプライヤーランキング
    • 主要企業のプロファイル
    • Eigen
    • Koninklijke Philips N.V.
    • Hitachi, Ltd.
    • MedCom
    • ESAOTE SPA
    • KOELIS
    • Focal Healthcare
    • GeoScan Medical
    • UC-Care Medical Systems Ltd.
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America fusion biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 4 North America fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 U.S. fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 6 U.S. fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Canada fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 8 Canada fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Europe fusion biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 11 Europe fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 U.K. fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 13 U.K. fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Germany fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 15 Germany fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Italy fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 17 Italy fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 France fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 19 France fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Spain fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 21 Spain fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 Denmark fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 23 Denmark fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Sweden fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 25 Sweden fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Norway fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 27 Norway fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific fusion biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Japan fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 32 Japan fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 India fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 34 India fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 China fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 36 China fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Thailand fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 38 Thailand fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 South Korea fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 40 South Korea fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Australia fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 42 Australia fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Latin America fusion biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 45 Latin America fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Brazil fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 47 Brazil fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Mexico fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 49 Mexico fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Argentina fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 51 Argentina fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 MEA fusion biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 54 MEA fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 55 South Africa fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 56 South Africa fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 UAE fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 60 UAE fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 62 Kuwait fusion biopsy market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1. Market research process
  • Fig. 2. Data triangulation techniques
  • Fig. 3. Primary research pattern
  • Fig. 4. Primary interviews in North America
  • Fig. 5. Primary interviews in Europe
  • Fig. 6. Primary interviews in APAC
  • Fig. 7. Primary interviews in Latin America
  • Fig. 8. Primary interviews in MEA
  • Fig. 9. Market research approaches
  • Fig. 10. Value-chain-based sizing & forecasting
  • Fig. 11. QFD modeling for market share assessment
  • Fig. 12. Market formulation & validation
  • Fig. 13. Fusion biopsy market: market outlook
  • Fig. 14. Fusion biopsy market competitive insights
  • Fig. 15. Parent market outlook
  • Fig. 16. Related/ancillary market outlook
  • Fig. 17. Penetration and growth prospect mapping
  • Fig. 18. Industry value chain analysis
  • Fig. 19. Fusion biopsy market driver impact
  • Fig. 20. Fusion biopsy market restraint impact
  • Fig. 21. Fusion biopsy market strategic initiatives analysis
  • Fig. 22. Fusion biopsy market: biopsy route movement analysis
  • Fig. 23. Fusion biopsy market: biopsy route outlook and key takeaways
  • Fig. 24. Transrectal market estimates and forecast, 2018 - 2030
  • Fig. 25. Transperineal market estimates and forecast, 2018 - 2030
  • Fig. 26. Fusion biopsy market: end-use movement analysis
  • Fig. 27. Fusion biopsy market: end-use outlook and key takeaways
  • Fig. 28. Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 29. Diagnostic centers market estimates and forecast, 2018 - 2030
  • Fig. 30. Ambulatory care centers market estimates and forecast, 2018 - 2030
  • Fig. 31. Fusion biopsy market: regional movement analysis
  • Fig. 32. Fusion biopsy market: regional outlook and key takeaways
  • Fig. 33. Fusion biopsy market share and leading players
  • Fig. 34. North America market share and leading players
  • Fig. 35. Europe market share and leading players
  • Fig. 36. Asia Pacific market share and leading players
  • Fig. 37. Latin America market share and leading players
  • Fig. 38. Middle East & Africa market share and leading players
  • Fig. 39. North America: SWOT
  • Fig. 40. Europe SWOT
  • Fig. 41. Asia Pacific SWOT
  • Fig. 42. Latin America SWOT
  • Fig. 43. MEA SWOT
  • Fig. 44. North America, by country
  • Fig. 45. North America
  • Fig. 46. North America market estimates and forecast, 2018 - 2030
  • Fig. 47. U.S.
  • Fig. 48. U.S. market estimates and forecast, 2018 - 2030
  • Fig. 49. Canada
  • Fig. 50. Canada market estimates and forecast, 2018 - 2030
  • Fig. 51. Europe
  • Fig. 52. Europe market estimates and forecast, 2018 - 2030
  • Fig. 53. UK
  • Fig. 54. UK market estimates and forecast, 2018 - 2030
  • Fig. 55. Germany
  • Fig. 56. Germany market estimates and forecast, 2018 - 2030
  • Fig. 57. France
  • Fig. 58. France market estimates and forecast, 2018 - 2030
  • Fig. 59. Italy
  • Fig. 60. Italy market estimates and forecast, 2018 - 2030
  • Fig. 61. Spain
  • Fig. 62. Spain market estimates and forecast, 2018 - 2030
  • Fig. 63. Denmark
  • Fig. 64. Denmark market estimates and forecast, 2018 - 2030
  • Fig. 65. Sweden
  • Fig. 66. Sweden market estimates and forecast, 2018 - 2030
  • Fig. 67. Norway
  • Fig. 68. Norway market estimates and forecast, 2018 - 2030
  • Fig. 69. Asia Pacific
  • Fig. 70. Asia Pacific market estimates and forecast, 2018 - 2030
  • Fig. 71. China
  • Fig. 72. China market estimates and forecast, 2018 - 2030
  • Fig. 73. Japan
  • Fig. 74. Japan market estimates and forecast, 2018 - 2030
  • Fig. 75. India
  • Fig. 76. India market estimates and forecast, 2018 - 2030
  • Fig. 77. Thailand
  • Fig. 78. Thailand market estimates and forecast, 2018 - 2030
  • Fig. 79. South Korea
  • Fig. 80. South Korea market estimates and forecast, 2018 - 2030
  • Fig. 81. Australia
  • Fig. 82. Australia market estimates and forecast, 2018 - 2030
  • Fig. 83. Latin America
  • Fig. 84. Latin America market estimates and forecast, 2018 - 2030
  • Fig. 85. Brazil
  • Fig. 86. Brazil market estimates and forecast, 2018 - 2030
  • Fig. 87. Mexico
  • Fig. 88. Mexico market estimates and forecast, 2018 - 2030
  • Fig. 89. Argentina
  • Fig. 90. Argentina market estimates and forecast, 2018 - 2030
  • Fig. 91. Middle East and Africa
  • Fig. 92. Middle East and Africa market estimates and forecast, 2018 - 2030
  • Fig. 93. South Africa
  • Fig. 94. South Africa market estimates and forecast, 2018 - 2030
  • Fig. 95. Saudi Arabia
  • Fig. 96. Saudi Arabia market estimates and forecast, 2018 - 2030
  • Fig. 97. UAE
  • Fig. 98. UAE market estimates and forecast, 2018 - 2030
  • Fig. 99. Kuwait
  • Fig. 100. Kuwait market estimates and forecast, 2018 - 2030
  • Fig. 101. Participant categorization - fusion biopsy market
  • Fig. 102. Market share of key market players - fusion biopsy market
目次
Product Code: GVR-4-68038-844-2

Fusion Biopsy Market Growth & Trends:

The global fusion biopsy market size is expected to reach USD 1,115.6 million by 2030, advancing at a CAGR of 8.6% during the forecast period, according to a new report by Grand View Research, Inc.. The increasing prevalence of prostate cancer, growing demand for targeted biopsy, and the rising utilization rate of multipara metric MRI in prostate cancer care are factors expected to drive the market during the forecast period. Moreover, factors such as rising awareness of the value of routine therapeutic interventions and emerging reimbursement policies are projected to drive demand in the market for fusion biopsy.

The high sensitivity and specificity of targeted fusion biopsy in delineating prostate lesions compared to other traditional technologies such as TRUS biopsy, PSA test, or Digital Rectal Examination is expected to contribute to the market growth. The reliability & reproducibility of the fusion biopsy system in the diagnosis of aggressive tumors is expected to make it a standard tool in prostate biopsy. An increasing number of radiologists gaining expertise in interpreting prostate MRI, coupled with the implementation of standard image grading systems such as PI-RADS and Gleason score, has increased the utilization rate of targeted MR/Ultrasound fusion biopsy systems.

The increasing number of government initiatives in terms of funding research, spreading awareness, and conducting mass screening programs related to prostate cancer are expected to play a crucial in the growth of the market. Some of the growth strategies adopted by market players include partnerships, product launches, participation in trade events and conferences, and acquisitions to drive and sustain growth in this highly competitive space.

Fusion Biopsy Market Report Highlights:

  • The transrectal segment held the largest market share in 2022, as it is the gold standard and commonly used method of prostate fusion biopsy
  • The transperineal segment is expected to grow at the fastest rate during the forecast period owing to the safety, diagnostic efficiency, and ability to access ventral prostate areas
  • The hospital segment accounted for the largest revenue share in 2022, owing to factors such as the increasing procurement rate of MR/US targeted fusion biopsy systems in teaching hospitals
  • The diagnostics centers segment is expected to expand at a significant rate over the forecast period. Shorter wait times, cost efficiency, and developing reimbursement paradigm are the factors expected to drive the growth of this segment
  • North America held the largest market share in 2022 and is anticipated to maintain its dominance over the forecast period
  • Asia Pacific is anticipated to witness a CAGR of 9.9% during the forecast period, owing to factors such as the growing awareness about the sensitivity and specificity of MRI/US targeted fusion biopsy systems among urologists, especially in countries such as Japan, Australia, and China

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Biopsy route
    • 1.1.2. End-use
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Biopsy route outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Fusion Biopsy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market driver analysis
      • 3.4.1.1. Increasing prevalence of prostate cancer
      • 3.4.1.2. Technological advancements in fusion imaging modalities
      • 3.4.1.3. Increasing funds and investments by public and private sector
    • 3.4.2. Market restraint analysis
      • 3.4.2.1. High cost of fusion biopsy system
      • 3.4.2.2. Liquid biopsy system
  • 3.5. Fusion Biopsy Market Analysis Tools
    • 3.5.1. Industry analysis - Porter's Five Forces
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape
    • 3.5.3. Major deals & strategic alliances analysis
    • 3.5.4. Market entry strategies
    • 3.5.5. COVID-19 Impact Analysis

Chapter 4. Fusion Biopsy Market: Biopsy Route Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Transrectal
    • 4.1.2. Transperineal
  • 4.2. Biopsy Route Market Share, 2022 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Global Fusion Biopsy Market by Biopsy Route Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.5.1. Transrectal
      • 4.5.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 4.5.2. Transperineal
      • 4.5.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)

Chapter 5. Fusion Biopsy Market: End-use Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Hospitals
    • 5.1.2. Diagnostic centers
    • 5.1.3. Ambulatory care centers
  • 5.2. End-use Market Share, 2022 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Fusion Biopsy Market by End-use Outlook
  • 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.5.1. Hospitals
      • 5.5.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. Diagnostic centers
      • 5.5.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. Ambulatory care centers
      • 5.5.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Fusion Biopsy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2022 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Regional Market Snapshot
  • 6.4. Regional Market Share and Leading Players, 2022
    • 6.4.1. North America
    • 6.4.2. Europe
    • 6.4.3. Asia Pacific
    • 6.4.4. Latin America
    • 6.4.5. Middle East and Africa
  • 6.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
    • 6.5.1. North America
    • 6.5.2. Europe
    • 6.5.3. Asia Pacific
    • 6.5.4. Latin America
    • 6.5.5. Middle East and Africa
  • 6.6. Market Size, & Forecasts and Trend Analysis, 2022 to 2030:
  • 6.7. North America
    • 6.7.1. U.S.
      • 6.7.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Canada
      • 6.7.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.8. Europe
    • 6.8.1. UK
      • 6.8.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.2. Germany
      • 6.8.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.3. France
      • 6.8.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.4. Italy
      • 6.8.4.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.5. Spain
      • 6.8.5.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.6. Denmark
      • 6.8.6.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.7. Sweden
      • 6.8.7.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.8. Norway
      • 6.8.8.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.9. Asia Pacific
    • 6.9.1. Japan
      • 6.9.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.9.2. China
      • 6.9.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.9.3. India
      • 6.9.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.9.4. South Korea
      • 6.9.4.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.9.5. Thailand
      • 6.9.5.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.9.6. Australia
      • 6.9.6.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.10. Latin America
    • 6.10.1. Brazil
      • 6.10.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.10.2. Mexico
      • 6.10.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.10.3. Argentina
      • 6.10.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.11. MEA
    • 6.11.1. South Africa
      • 6.11.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.11.2. Saudi Arabia
      • 6.11.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.11.3. UAE
      • 6.11.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.11.4. Kuwait
      • 6.11.4.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competitive Categorization
    • 7.2.1. Innovators
    • 7.2.2. Market leaders
    • 7.2.3. Emerging players
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2019
  • 7.4. Public Companies
    • 7.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 7.4.2. Company market share/ranking, by region
    • 7.4.3. Competitive dashboard analysis
      • 7.4.3.1. Market differentiators
      • 7.4.3.2. Synergy analysis: major deals and strategic alliances
  • 7.5. Private Companies
    • 7.5.1. List of key emerging companies/technology disruptors/innovators
    • 7.5.2. Funding outlook
    • 7.5.3. Regional network map
    • 7.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
    • 7.5.5. Supplier ranking
    • 7.5.6. Key company profiled
    • 7.5.7. Eigen
      • 7.5.7.1. Company overview
      • 7.5.7.2. Financial performance
      • 7.5.7.3. Product benchmarking
      • 7.5.7.4. Strategic initiatives
    • 7.5.8. Koninklijke Philips N.V.
      • 7.5.8.1. Company overview
      • 7.5.8.2. Financial performance
      • 7.5.8.3. Product benchmarking
      • 7.5.8.4. Strategic initiatives
    • 7.5.9. Hitachi, Ltd.
      • 7.5.9.1. Company overview
      • 7.5.9.2. Financial performance
      • 7.5.9.3. Product benchmarking
      • 7.5.9.4. Strategic initiatives
    • 7.5.10. MedCom
      • 7.5.10.1. Company overview
      • 7.5.10.2. Financial performance
      • 7.5.10.3. Product benchmarking
      • 7.5.10.4. Strategic initiatives
    • 7.5.11. ESAOTE SPA
      • 7.5.11.1. Company overview
      • 7.5.11.2. Financial performance
      • 7.5.11.3. Product benchmarking
      • 7.5.11.4. Strategic initiatives
    • 7.5.12. KOELIS
      • 7.5.12.1. Company overview
      • 7.5.12.2. Financial performance
      • 7.5.12.3. Product benchmarking
      • 7.5.12.4. Strategic initiatives
    • 7.5.13. Focal Healthcare
      • 7.5.13.1. Company overview
      • 7.5.13.2. Financial performance
      • 7.5.13.3. Product benchmarking
      • 7.5.13.4. Strategic initiatives
    • 7.5.14. GeoScan Medical
      • 7.5.14.1. Company overview
      • 7.5.14.2. Financial performance
      • 7.5.14.3. Product benchmarking
      • 7.5.14.4. Strategic initiatives
    • 7.5.15. UC-Care Medical Systems Ltd.
      • 7.5.15.1. Company overview
      • 7.5.15.2. Financial performance
      • 7.5.15.3. Product benchmarking
      • 7.5.15.4. Strategic initiatives